Intensity Therapeutics (INTS) awards CFO 34,000 stock options at $4.90
Rhea-AI Filing Summary
Intensity Therapeutics granted its Chief Financial Officer, Joseph Talamo, a stock option for 34,000 shares of Common Stock on July 16, 2026. The option has a $4.90 per-share exercise price and expires on July 16, 2036.
According to the terms, the option will vest in four equal annual installments beginning July 16, 2027, conditioned on his continued service with the company. Following this grant, Talamo holds 34,000 stock options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Talamo Joseph
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy Common Stock) F1 | 34,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy Common Stock) — 34,000 shares (Direct)
Footnotes (1)
- F1. This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2027.
Key Figures
Stock options granted: 34,000 shares
Exercise price: $4.90 per share
Shares underlying option: 34,000 shares
+2 more
5 metrics
Stock options granted
34,000 shares
Grant of Stock Option to CFO on July 16, 2026
Exercise price
$4.90 per share
Conversion or exercise price of the Stock Option
Shares underlying option
34,000 shares
Common Stock underlying the Stock Option grant
Vesting schedule
4 annual installments
Option vests in four equal annual installments beginning July 16, 2027
Expiration date
July 16, 2036
Option expiration stated for the Stock Option grant
Key Terms
Stock Option (right to buy Common Stock), conversion or exercise price, vesting
3 terms
Stock Option (right to buy Common Stock) financial
"security_title: Stock Option (right to buy Common Stock)"
conversion or exercise price financial
"conversion_or_exercise_price: 4.9000"
vesting financial
"This option will vest, subject to the individual's continued service"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Intensity Therapeutics (INTS) report for CFO Joseph Talamo?
Intensity Therapeutics reported that CFO Joseph Talamo received a grant of 34,000 stock options for Common Stock. These options have a $4.90 exercise price per share and represent a compensation-related award rather than an open-market purchase or sale of existing shares.
How many Intensity Therapeutics (INTS) options did the CFO receive and at what exercise price?
CFO Joseph Talamo received 34,000 stock options linked to Intensity Therapeutics Common Stock. The options carry a $4.90 per-share exercise price, meaning he can purchase shares at that price once the options have vested and are exercised before expiration.
When do Joseph Talamo’s Intensity Therapeutics (INTS) stock options vest?
The stock options granted to CFO Joseph Talamo will vest in four equal annual installments starting on July 16, 2027. Vesting is explicitly conditioned on his continued service with Intensity Therapeutics, so remaining employed is required to receive each installment.
When do the CFO’s Intensity Therapeutics (INTS) stock options expire?
The granted stock options are scheduled to expire on July 16, 2036. Talamo may exercise vested options at the $4.90 per-share price any time after vesting and before that expiration date, subject to the company’s applicable equity plan terms and policies.
Were the Intensity Therapeutics (INTS) CFO option grants made under a Rule 10b5-1 trading plan?
The filing shows the Rule 10b5-1 checkbox was not marked, so the transaction was not reported as made under a Rule 10b5-1 trading plan. It is disclosed as a standard equity compensation grant rather than as part of a pre-arranged trading program.
How many Intensity Therapeutics (INTS) derivative securities does the CFO hold after this grant?
Following this award, CFO Joseph Talamo is reported as directly holding 34,000 stock options related to Intensity Therapeutics Common Stock. This figure reflects the total derivative securities from this specific grant as of the reported transaction date in the Form 4.